This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Hypertension is a condition that requires continuous monitoring, making it an ideal candidate for telehealth and digital health innovations. Why Telehealth is Essential for Hypertension For patients with hypertension, managing bloodpressure outside of the office is crucial. Who Should Use Video Visits?
The retrospective analysis of data from the MODERATO II study demonstrated that AVIM therapy significantly improved echocardiographic (Echo) markers of diastolic dysfunction, an important component in the development of heart failure, in hypertensive patients. Senior Vice President of Medical Affairs and Innovation at Orchestra BioMed.
a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases, hasannounced that the U.S. We believe suppression of aldosterone production by lorundrostat has the potential to reduce the nocturnal hypertension driving adverse cardiovascular outcomes.
BackgroundSmartphone applications and wearable devices are promising mobile health interventions for hypertension self‐management. Participants in both groups are followed for up for 6 months with a primary end point of change in systolic bloodpressure.
These groundbreaking developments offer a paradigm shift in the management of resistant hypertension, especially when it is extremely difficult to achieve bloodpressure control through conventional means, such as lifestyle modifications and various drug therapies.
By understanding patterns in heart rate, bloodpressure, and oxygen levels, surgeons can tailor procedures to the individuals needs. Risk Reduction Data from wearables can identify potential risks, such as undiagnosed arrhythmias or hypertension, allowing healthcare teams to address these issues before surgery.
BACKGROUND:Remote health management programs utilizing evidence-based algorithm-driven virtual care solutions for chronic disease management offer a novel approach to addressing implementation gaps for conditions such as hypertension. Most provider participants were female (n=4), and all were medical doctors.
ET Main Tent (Hall B1) Effect of Gamification, Financial Incentives or Both Combined to Increase Physical Activity Among Patients with Elevated Risk For Major Adverse Cardiovascular Events.
Introduction/Background:The American Heart Association’s National Hypertension Control Initiative (NHCI) collaborated with health care professionals and public health advocates to facilitate listening sessions for learning collaboratives (LCs) to discuss ways to address hypertension (HTN) through Clinical-Community Linkages (CCL) in five regions.
History & Future of Cardiac Remote Patient Monitoring Healthcare reforms fueled by government legislation and recent technological innovations have propelled cardiac remote patient monitoring to the forefront in the early 2020s, but the history of cardiac remote patient monitoring dates to more than half a century ago.
A new peer-reviewed study published in the Journal of the American Heart Association , JAHA, found that Hello Heart’s digital heart health program was associated with reductions in bloodpressure (BP), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and weight. of their body weight.
Hypertension, Ahead of Print. Hypertension, a leading cause of cardiovascular disease and premature death, remains incompletely understood despite extensive research. Indeed, even though numerous drugs are available, achieving adequate bloodpressure control remains a challenge, prompting recent interest in artificial intelligence.
“We are witnessing a paradigm shift in how valvular heart diseases are diagnosed and treated,” said Partho Sengupta , Henry Rutgers Professor of Cardiology and chief of the Division of Cardiovascular Disease and Hypertension at Rutgers Robert Wood Johnson Medical School. Is There Medication for Valvular Heart Disease?
February 2024 FDA Approvals: Innovations in Cardiovascular Interventions XACT Carotid Stent System (Approved: 02/07/2024) This approval expands the indications to be used during a Transcarotid Artery Revascularization (TCAR) procedure to prevent future strokes.
From breakthrough medications to innovative technologies, there is a lot for cardiometabolic clinicians professionals to celebrate. The study found reductions in the apnea-hypopnea index (AHI), inflammation markers, and systolic bloodpressure, making it a promising dual-purpose medication for managing obesity-related complications.
13, 2025 Medtronic recentlyannounced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension.
Attendees, including hundreds of health professionals, gained access to the latest knowledge and developments in the field, from exclusive insights from one of the foremost authorities on atherosclerosis, Dr. Peter Libby, to innovations like new therapeutic agents and exciting advancements in renal protection. In the U.S.,
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content